Guardian Capital Advisors (Canada)’s AbCellera Biologics ABCL Stock Holding History

Guardian Capital Advisors (Canada)’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.59M	Hold	1,786,414	–	–	0.45%	65
2024 Q2	$5M	Hold	1,786,414	–	–	0.53%	61
2024 Q1	$7M	Hold	1,786,414	–	–	0.75%	47
2023 Q4	$10.7M	Hold	1,786,414	–	–	1.11%	29
2023 Q3	$7.84M	Hold	1,786,414	–	–	0.88%	38
2023 Q2	$13.5M	Hold	1,786,414	–	–	1.53%	18
2023 Q1	$13M	Hold	1,786,414	–	–	1.5%	20
2022 Q4	$18.2M	Sell	1,786,414 -1,950,000	-52%	-$22.5M	2.07%	11
2022 Q3	$40.1M	Sell	3,736,414 -100,000	-3%	-$1.1M	5.01%	3
2022 Q2	$44.4M	Hold	3,836,414	–	–	5.09%	3
2022 Q1	$34.6M	Hold	3,836,414	–	–	3.37%	5
2021 Q4	$45.3M	Hold	3,836,414	–	–	4.36%	3
2021 Q3	$76.8M	Sell	3,836,414 -139,580	-4%	-$2.47M	7.97%	1
2021 Q2	$81.4M	Buy	+3,975,994	New	+$110M	8.35%	1

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Guardian Capital Advisors (Canada)'s ABCL Position: Q3 2024 in Review

Guardian Capital Advisors (Canada) held its AbCellera Biologics (ABCL) position steady in Q3 2024 at 1,786,414 shares worth $4.59M. The position accounts for 0.45% of the portfolio, ranked #65.

Guardian Capital Advisors (Canada) first reported a position in ABCL in Q2 2021 and has held it in 14 quarters since. The position peaked at $81.4M in Q2 2021. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Guardian Capital Advisors (Canada) held 1,786,414 shares of AbCellera Biologics worth $4.59M as of Q3 2024.
Guardian Capital Advisors (Canada) left its AbCellera Biologics share count unchanged in Q3 2024.
AbCellera Biologics made up 0.45% of Guardian Capital Advisors (Canada)'s portfolio in Q3 2024, its #65 holding.
Guardian Capital Advisors (Canada) first reported a position in AbCellera Biologics in Q2 2021 and has held it in 14 quarters since.
Guardian Capital Advisors (Canada)'s AbCellera Biologics position peaked at $81.4M in Q2 2021.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Guardian Capital Advisors (Canada)'s 13F filing for Q3 2024, filed 12 Nov 2024.